DLT

MicroAlgo Inc. Developed QSDLT to Provide a More Secure Foundation for Bitcoin and Other Cryptocurrency Systems

Retrieved on: 
Wednesday, December 27, 2023
Quantum, Computer, Blockchain, Deep learning, Research, DLT, History, Machine learning, Face, Growth, RSA, Algorithm, Cryptocurrency

BEIJING, Dec. 27, 2023 /PRNewswire/ -- MicroAlgo Inc. (NASDAQ: MLGO) (the "Company" or "MicroAlgo"), today announced the quantum shield distributed ledger technology (QSDLT), designed to provide a stronger, more secure foundation for Bitcoin and other cryptocurrency systems.

Key Points: 
  • BEIJING, Dec. 27, 2023 /PRNewswire/ -- MicroAlgo Inc. (NASDAQ: MLGO) (the "Company" or "MicroAlgo"), today announced the quantum shield distributed ledger technology (QSDLT), designed to provide a stronger, more secure foundation for Bitcoin and other cryptocurrency systems.
  • To protect the Bitcoin system from the threat of quantum computers, MicroAlgo Inc.'s QSDLT was created as an innovative solution.
  • MicroAlgo Inc.'s QSDLT provides the Bitcoin system with a robust defence against quantum algorithms with its strong anti-quantum algorithmic capabilities, making transactions secure and tamper-proof.
  • As the threat of quantum computing emerges, the emergence of MicroAlgo Inc.'s QSDLT marks the dawn of a new era of Bitcoin security.

CellOrigin announced treatment of the first patient with CAR-M in China and reported the second generation of CAR-M for solid tumors

Retrieved on: 
Wednesday, December 20, 2023
Quality of life, C-reactive protein, Research group, Fever, Tumor microenvironment, National academy, Biotechnology, Research, DLT, Cytokine release syndrome, CMC, TIR, Trial of the century, Metabolism, Macrophage, Zhejiang University, Pharmacokinetics, Neurotoxicity, Common, Patient, Safety, PNAS, Pharmaceutical industry

The successful completion of the first patient dosing of SY001  demonstrates the advanced technology of the company's R&D platform and the maturity of the CMC platform.

Key Points: 
  • The successful completion of the first patient dosing of SY001  demonstrates the advanced technology of the company's R&D platform and the maturity of the CMC platform.
  • Only 2 grade 3 adverse events occurred; Common grade 1 - 2 adverse events included fever, elevated C-reactive protein, etc.
  • Based on M-CAR, a functionally enhanced second generation CAR-iMAC has been developed to enhance the effectiveness of the therapy for solid tumors.
  • The mechanism of antigen-dependent activation and polarization of the second generation CAR-iMAC and the mechanisms of solid tumor cell killing were also revealed.

Immatics Announces Third Quarter 2023 Financial Results and Business Update

Retrieved on: 
Tuesday, November 14, 2023
Senior, Entrepreneurship, CRS, Peptide, Regenerative Medicine Advanced Therapy, Patient, Triple-negative breast cancer, Cell, Research, Pharmacology, Therapy, Conference, ORR, Neurotoxicity, Infrared spectroscopy correlation table, Cytokine release syndrome, Uveal melanoma, Bristol Myers Squibb, Safety, Head, Cancer, Administration, CD4, PRAME, Uterine cancer, Lung cancer, Melanoma, Ovarian cancer, Half-life, Development, SAB, BRAF, CD8, MAGEA4, Cytopenia, TCR, Protein, FDA, DLT, Messenger, Cmax, Toxic epidermal necrolysis, Sarcoma, CMC, Neoplasm, Vaccine, Medical imaging, Pharmaceutical industry, Cryptocurrency, Fine chemical, Drug, Moderna, NSCLC

“Immatics has had a strong quarter and made steady progress both in terms of the advancement of our clinical programs and in business development.

Key Points: 
  • “Immatics has had a strong quarter and made steady progress both in terms of the advancement of our clinical programs and in business development.
  • An update on the clinical development plan is expected in the first quarter of 2024.
  • An update on the clinical development plan is expected in the first quarter of 2024.
  • On September 11, Immatics announced a strategic multi-platform collaboration with Moderna, combining Immatics’ target and TCR platforms with Moderna’s cutting-edge mRNA technology.

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023

Retrieved on: 
Monday, December 11, 2023
Pharmaceutical, Health, Oncology, Clinical Trials, Pharmacokinetics, BCL2, Safety, Toxicity, Lymphoid leukemia, Acute myeloid leukemia, ASH, Cohort, Dana–Farber Cancer Institute, Cellular, Clinical research, Fatigue, Patient, CDK9, Division, DLT, Exposition, Index, Bone marrow, MD, Diarrhea, Nausea, MTD, Half-life, Transplant, AML, Biomarker, Anemia, MMSc, Infrared spectroscopy correlation table, Society, Failure, Poster, Venetoclax, Pharmaceutical industry, Vaccine, Lymphoma

The poster can be viewed on the MEI Pharma website here: https://meipharma.com/ash2023.html .

Key Points: 
  • The poster can be viewed on the MEI Pharma website here: https://meipharma.com/ash2023.html .
  • The second stage of the study is ongoing and is evaluating voruciclib in combination with venetoclax in patients with R/R AML.
  • The primary objectives of the study are to determine the safety and biologic effective dose of voruciclib monotherapy or voruciclib in combination with venetoclax.
  • Secondary objectives of the study include assessing the preliminary efficacy, pharmacokinetics, pharmacodynamics, and biomarkers of voruciclib monotherapy or voruciclib in combination with venetoclax.

OliX Pharmaceuticals Announces Positive Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212 for Age-Related Macular Degeneration

Retrieved on: 
Wednesday, November 29, 2023
Seniors, Biotechnology, Pharmaceutical, Optical, Health, Genetics, Consumer, Clinical Trials, Intravitreal injection, Safety, Neovascularization, Visual acuity, RNA interference, Homeostasis, Vance DeGeneres, Patient, Small RNA, DLT, Therapy, RNA, Harvard Medical School, AMD, Macular degeneration, Sirna Therapeutics, KOSDAQ, Quality of life, Paratriathlon, Inflammation, Optimism, Pharmaceutical industry

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced positive results from a Phase 1 study evaluating the safety and tolerability of OLX10212 for the treatment of Age-Related Macular Degeneration (AMD).

Key Points: 
  • OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced positive results from a Phase 1 study evaluating the safety and tolerability of OLX10212 for the treatment of Age-Related Macular Degeneration (AMD).
  • This phase 1 study is a multi-center, single-dose, dose-escalating study to evaluate the safety and tolerability of OLX10212 in patients with neovascular AMD.
  • The primary endpoints of this study were safety and tolerability assessments associated with each intravitreal OLX10212 injection.
  • The safety and tolerability evaluations, together with preliminary BCVA improvement of OLX10212 encourage further development of OLX10212 for AMD.

Capgemini Collaborates with Euroclear for Successful Launch of Digital Financial Market Infrastructure (D-FMI)

Retrieved on: 
Tuesday, November 21, 2023
Technology, Finance, Security, Carriers and Services, Banking, Accounting, Professional Services, Software, Digital Cash Management, Digital Assets, Data Management, DLT, Growth, Financial services, Safety, Digital, DNN, Partnership, Euroclear, Cryptocurrency, Capgemini

Capgemini announced today the recent collaboration with Euroclear to successfully launch its Digital Securities Issuance (D-SI) service, the first key milestone of Euroclear’s Digital Financial Market Infrastructure (D-FMI) strategy.

Key Points: 
  • Capgemini announced today the recent collaboration with Euroclear to successfully launch its Digital Securities Issuance (D-SI) service, the first key milestone of Euroclear’s Digital Financial Market Infrastructure (D-FMI) strategy.
  • Capgemini acted as the lead system integrator on the D-FMI program, providing a comprehensive range of services, including consulting, design, implementation, and testing.
  • Capgemini was also involved in the overall integration and orchestration of the new D-FMI platform within Euroclear’s existing systems and infrastructure.
  • “We are proud to partner with Euroclear to revolutionize the traditional financial market infrastructure through the D-FMI program.

Raiffeisen Schweiz Joins SIX Digital Exchange, Expanding the Digital Financial Landscape in Switzerland

Retrieved on: 
Monday, December 18, 2023
Digital asset, DLT, FINMA, SDX, SIX, CSD, SIS, Cryptocurrency, Raiffeisen (Switzerland)

ZURICH and LENZBURG, Switzerland, Dec. 18, 2023 /PRNewswire/ – Raiffeisen Schweiz , a leading Swiss banking group, joins SDX , the world's first fully regulated financial market infrastructure for digital assets.

Key Points: 
  • ZURICH and LENZBURG, Switzerland, Dec. 18, 2023 /PRNewswire/ – Raiffeisen Schweiz , a leading Swiss banking group, joins SDX , the world's first fully regulated financial market infrastructure for digital assets.
  • SDX, licensed by the Swiss Financial Market Supervisory Authority (FINMA), operates a stock exchange and CSD utilizing distributed ledger technology (DLT).
  • These memberships position Raiffeisen Schweiz at the forefront of the digital asset revolution and align with its ambition to issue native digital products upon joining the SDX CSD.
  • "By joining the SDX ecosystem, Raiffeisen Switzerland increases its footprint and experience in digital assets with the aim of actively contributing to the development of the digital assets industry and product landscape", says Werner Leuthard, Head of Trading at Raiffeisen Switzerland.

Shaping the Future of Compliance in Digital Assets

Retrieved on: 
Thursday, December 14, 2023
Risk management, Risk assessment, DLT, Documentation, KYC, Partnership, Software as a service, AML, KYT, Jaybee Sebastian, Fintech, Cryptocurrency

MarketGuard, offering innovative crypto compliance solutions, aimed to upgrade its SaaS platform to address the rapidly changing digital currency landscape.

Key Points: 
  • MarketGuard, offering innovative crypto compliance solutions, aimed to upgrade its SaaS platform to address the rapidly changing digital currency landscape.
  • JayBee, a Swiss company specialised in compliance, regulation, and risk management with a strong focus on DLT & FinTech, emerged as the perfect strategic partner.
  • We're not just adapting to the digital currency landscape; we're leading the way towards a safer, more compliant financial future."
  • MarketGuard and JayBee are actively shaping the future of compliance in digital currencies, promising ongoing innovation and setting new benchmarks in crypto compliance.

Shaping the Future of Compliance in Digital Assets

Retrieved on: 
Thursday, December 14, 2023
Risk management, Risk assessment, DLT, Documentation, KYC, Partnership, Software as a service, AML, KYT, Jaybee Sebastian, Fintech, Cryptocurrency

MarketGuard, offering innovative crypto compliance solutions, aimed to upgrade its SaaS platform to address the rapidly changing digital currency landscape.

Key Points: 
  • MarketGuard, offering innovative crypto compliance solutions, aimed to upgrade its SaaS platform to address the rapidly changing digital currency landscape.
  • JayBee, a Swiss company specialised in compliance, regulation, and risk management with a strong focus on DLT & FinTech, emerged as the perfect strategic partner.
  • We're not just adapting to the digital currency landscape; we're leading the way towards a safer, more compliant financial future."
  • MarketGuard and JayBee are actively shaping the future of compliance in digital currencies, promising ongoing innovation and setting new benchmarks in crypto compliance.

Charles Adkins Appointed as President of the Hedera Council

Retrieved on: 
Wednesday, December 13, 2023
Red Bull, Organization, Department of the Treasury, The Walt Disney Company, Nike, Morgan Stanley, DLT, Treasury, Financial services, Strategy, Final good, Polygon, EY, Personal ordinariate, Microsoft, Government, Management, Hedera

LAS VEGAS, Dec. 13, 2023 /PRNewswire/ -- The Hedera Council today announced the appointment of Charles Adkins as its new President. Adkins brings a wealth of experience in web 3 technology – including key roles at prominent web3 organizations such as Aptos and Polygon – as well as in finance, government, and consumer brands, making him a valuable addition to the Hedera leadership team and bringing a new set of relationships to the Hedera ecosystem.

Key Points: 
  • New President Has Held Leadership Roles at Aptos, Polygon, the Treasury Department and at Leading Consumer Products and Financial Services Firms
    LAS VEGAS, Dec. 13, 2023 /PRNewswire/ -- The Hedera Council today announced the appointment of Charles Adkins as its new President.
  • Adkins expressed his excitement about joining Hedera.
  • Brett McDowell, Chair of the Hedera Council, commented, "We are thrilled to have Charles join us as President.
  • His caliber of experience and expertise in financial services, government administration, go-to-market strategy, and web3 technology uniquely qualifies Charles to serve as the next President of Hedera.